Porfimer sodium

Drug Profile

Porfimer sodium

Alternative Names: CL 184116; Photobarr; Photofrin; Photofrin II; Photofrin PDT; Photofrin Photodynamic Therapy - Axcan Pharma

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QLT
  • Developer Adare Pharmaceuticals; Novelion Therapeutics; Pinnacle Biologics; Roswell Park Cancer Institute; University of Pennsylvania
  • Class Antineoplastics; Hematoporphyrins
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - High-grade oesophageal dysplasia; Cholangiocarcinoma; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bladder cancer; Cervical cancer; Cervical dysplasia; Gastric cancer; High-grade oesophageal dysplasia; Non-small cell lung cancer; Oesophageal cancer
  • Phase III Cholangiocarcinoma
  • Phase II Brain cancer; Mesothelioma

Most Recent Events

  • 14 Aug 2017 Concordia Laboratories initiates enrolment in a phase I trial for Non-small cell lung cancer in USA (NCT03344861)
  • 26 Jan 2017 Concordia Laboratories initiates enrolment in a phase I trial for Non-small cell lung cancer (Unresectable) in USA and Canada (NCT02916745)
  • 19 Dec 2016 Concordia International terminates the phase III OPUS trial in Cholangiocarcinoma due to slow patient acrual in USA, Canada, Germany, South Korea and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top